C4 Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$3.10

−3.43%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:00 IST · A quote does not mean the product is available to trade on your account.

Day's open: $3.36
Previous close: $3.21
Volume: 2.0M
Day's high: $3.39
Day's low: $3.02

In brief

C4 Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $381M.
Its shares closed at $3.12 on 4 Nov 2026, up 38.1% over the past year.
From India you can buy CCCC in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy C4 Therapeutics, Inc. (CCCC) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole CCCC share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade CCCC options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +8.3% (SPY −1.6%, XLV +13.5%). 3 months: −13.8% (SPY −0.4%, XLV +15.5%). 1 year: +38.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: CCCC, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $3.12 was 4.5% below its 50-day average ($3.27) and 3.2% below its 200-day average ($3.22). It has closed below the 200-day for 3 sessions, since 2 Nov 2026. The 50-day average crossed above the 200-day on 10 Mar 2026, 166 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
16.9 days to cover short interest
42.7M shares were sold short at the 15 Oct 2026 settlement, 34.7% of the 123.0M shares outstanding; covering them would take 16.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
41% of the way up its 52-week range
Closed at $3.12 on 4 Nov 2026: 39.7% below the 52-week high of $5.17 (30 Jun 2026) and 84.6% above the low of $1.69 (5 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+8.3%

6 months+6.5%

1 year+38.1%

5 years−93.1%

Newswire

About

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Website

Notable moves

December 13, 2023
+135.47%
December 12, 2023
+98.31%
April 8, 2022
−50.57%

Newswire

About

Website

Notable moves

December 13, 2023
+135.47%
December 12, 2023
+98.31%
April 8, 2022
−50.57%

C4 Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$3.10

−3.43%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:00 IST · A quote does not mean the product is available to trade on your account.

Day's open: $3.36
Previous close: $3.21
Volume: 2.0M
Day's high: $3.39
Day's low: $3.02

In brief

C4 Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $381M.
Its shares closed at $3.12 on 4 Nov 2026, up 38.1% over the past year.
From India you can buy CCCC in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy C4 Therapeutics, Inc. (CCCC) shares from India?

Do I need the price of a whole CCCC share to invest?

How much can I invest in US stocks in a year?

Can I trade CCCC options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +8.3% (SPY −1.6%, XLV +13.5%). 3 months: −13.8% (SPY −0.4%, XLV +15.5%). 1 year: +38.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: CCCC, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $3.12 was 4.5% below its 50-day average ($3.27) and 3.2% below its 200-day average ($3.22). It has closed below the 200-day for 3 sessions, since 2 Nov 2026. The 50-day average crossed above the 200-day on 10 Mar 2026, 166 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
16.9 days to cover short interest
42.7M shares were sold short at the 15 Oct 2026 settlement, 34.7% of the 123.0M shares outstanding; covering them would take 16.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
41% of the way up its 52-week range
Closed at $3.12 on 4 Nov 2026: 39.7% below the 52-week high of $5.17 (30 Jun 2026) and 84.6% above the low of $1.69 (5 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+8.3%

6 months+6.5%

1 year+38.1%

5 years−93.1%

Newswire

About

Website

Notable moves

December 13, 2023
+135.47%
December 12, 2023
+98.31%
April 8, 2022
−50.57%

Newswire

About

Website

Notable moves

December 13, 2023
+135.47%
December 12, 2023
+98.31%
April 8, 2022
−50.57%

C4 Therapeutics, Inc.

C4 Therapeutics, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

Below its 50- and 200-day averages

16.9 days to cover short interest

41% of the way up its 52-week range

C4 Therapeutics, Inc.

C4 Therapeutics, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

Below its 50- and 200-day averages

16.9 days to cover short interest

41% of the way up its 52-week range